Molecular aspects of glutamate dysregulation: Implications for schizophrenia and its treatment

Pharmacology and Therapeutics

Volumn 97, Issue 2, 2003, Pages 153-179

  Konradi, Christine ^a,b,c   Heckers, Stephan ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Antipsychotic drugs; Glutamate; Neuropathology; Neuroplasticity; Neurotoxicity; Schizophrenia

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 CARBOXY 2 METHYLPHENYLGLYCINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

DOPAMINERGIC SYSTEM; HUMAN; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SYNAPSE;

EID: 0037305349     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00328-5     Document Type: Review

References (369)

1. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev. 31:2000;302-312.
2. Ahmari S.E., Buchanan J., Smith S.J. Assembly of presynaptic active zones from cytoplasmic transport packets. Nat Neurosci. 3:2000;445-451.
3. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E. Jr., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci. 16:1996;19-30.
4. Alnemri E.S. Mammalian cell death proteases: a family of highly conserved aspartate specific cysteine proteases. J Cell Biochem. 64:1997;33-42.
5. Andersson C., Chakos M., Mailman R., Lieberman J. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. Psychiatr Clin North Am. 21:1998;151-179.
6. Andreasen N.C. Pieces of the schizophrenia puzzle fall into place. Neuron. 16:1996;697-700.
7. Andreasen N.C. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev. 31:2000;106-112.
8. Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol. 61:2000;525-541.
9. Ankarcrona M., Dypbukt J.M., Bonfoco E., Zhivotovsky B., Orrenius S., Lipton S.A., Nicotera P. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 15:1995;961-973.
10. Aparicio-Legarza M.I., Davis B., Hutson P.H., Reynolds G.P. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett. 241:1998;143-146.
11. Aramori I., Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron. 8:1992;757-765.
12. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther. 283:1997;226-234.
13. Ascher P., Nowak L. Electrophysiological studies of NMDA receptors. Trends Neurosci. 10:1987;284-287.
14. Bailey C.H., Bartsch D., Kandel E.R. Toward a molecular definition of long-term memory storage. Proc Natl Acad Sci USA. 93:1996;13445-13452.
15. Banerjee S.P., Zuck L.G., Yablonsky-Alter E., Lidsky T.I. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport. 6:1995;2500-2504.
16. Baruah S., Waziri R., Sherman A. Neuroleptic effects on serine and glycine metabolism. Biol Psychiatry. 34:1993;544-550.
17. Bear M.F., Malenka R.C. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol. 4:1994;389-399.
18. Beattie E.C., Carroll R.C., Yu X., Morishita W., Yasuda H., von Zastrow M., Malenka R.C. Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat Neurosci. 3:2000;1291-1300.
19. Becker T., Elmer K., Schneider F., Schneider M., Grodd W., Bartels M., Heckers S., Beckmann H. Confirmation of reduced temporal limbic structure volume on magnetic resonance imaging in male patients with schizophrenia. Psychiatry Res. 67:1996;135-143.
20. Benes F.M. Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol Psychiatry. 46:1999;589-599.
21. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 25:2001;1-27.
22. Benes F.M., Paskevich P.A., Davidson J., Domesick V.B. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res. 329:1985;265-273.
23. Bergeron L., Yuan J. Sealing one's fate: control of cell death in neurons. Curr Opin Neurobiol. 8:1998;55-63.
24. 2+- and stimulus duration-dependent switch for hippocampal gene expression. Cell. 87:1996;1203-1214.
25. Boegman R.J., Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse. 22:1996;70-77.
26. Bolonna A.A., Kerwin R.W., Munro J., Arranz M.J., Makoff A.J. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr Res. 47:2001;99-103.
27. Bortolotto Z.A., Fitzjohn S.M., Collingridge G.L. Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Curr Opin Neurobiol. 9:1999;299-304.
28. Bourtchuladze R., Frenguelli B., Blendy J., Cioffi D., Schutz G., Silva A.J. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell. 79:1994;59-68.
29. Bray N.J., Williams N.M., Bowen T., Cardno A.G., Gray M., Jones L.A., Murphy K.C., Sanders R.D., Spurlock G., Odonovan M.C., Owen M.J. No evidence for association between a non-synonymous polymorphism in the gene encoding human metabotropic glutamate receptor 7 and schizophrenia. Psychiatr Genet. 10:2000;83-86.
30. Bredesen D.E. Neural apoptosis. Ann Neurol. 38:1995;839-851.
31. Breese C.R., Freedman R., Leonard S.S. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674:1995;82-90.
32. Brene S., Messer C., Nestler E.J. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: regulation by haloperidol. Neuroscience. 84:1998;813-823.
33. Brimecombe J.C., Gallagher M.J., Lynch D.R., Aizenman E. An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 286:1998;627-634.
34. Bromet E.J., Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry. 46:1999;871-881.
35. Bunney B.G., Potkin S.G., Bunney W.E. Neuropathological studies of brain tissue in schizophrenia. J Psychiatr Res. 31:1997;159-173.
36. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology. 124:1996;87-94.
37. 1-adrenergic receptors in vitro. Schizophr Res. 37:1999;107-122.
38. Canton H., Verriele L., Colpaert F.C. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Eur J Pharmacol. 191:1990;93-96.
39. Carpenter W.T. Jr., Buchanan R.W. Schizophrenia. New Engl J Med. 330:1994;681-690.
40. Carr D.B., Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci. 20:2000;3864-3873.
41. Carr D.B., O'Donnell P., Card J.P., Sesack S.R. Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cells that project to the nucleus accumbens. J Neurosci. 19:1999;11049-11060.
42. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 75:2000;889-907.
43. Cartmell J., Monn J.A., Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology. 148:2000;423-429.
44. Carvalho A.L., Kameyama K., Huganir R.L. Characterization of phosphorylation sites on the glutamate receptor 4 subunit of the AMPA receptors. J Neurosci. 19:1999;4748-4754.
45. Casey D.E. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 35:1999;S61-S66.
46. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 61(suppl. 4):2000;5-9.
47. Cassady S.L., Adami H., Moran M., Kunkel R., Thaker G.K. Spontaneous dyskinesia in schizophrenia spectrum personality. Am J Psychiatry. 155:1998;70-75.
48. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA. 90:1993;9576-9580.
49. 2 dopamine receptor-deficient mice. J Neurophysiol. 85:2001;659-670.
50. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry. 151:1994;1430-1436.
51. Chakos M.H., Shirakawa O., Lieberman J., Lee H., Bilder R., Tamminga C.A. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry. 44:1998;675-684.
52. Chapman M.A., See R.E. Differential effects of unique profile antipsychotic drugs on extracellular amino acids in the ventral pallidum and globus pallidus of rats. J Pharmacol Exp Ther. 277:1996;1586-1594.
53. Choi D.W. Ionic dependence of glutamate neurotoxicity. J Neurosci. 7:1987;369-379.
54. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
55. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 13:1990;171-182.
56. Clements J.D., Westbrook G.L. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron. 7:1991;605-613.
57. Connor J.A., Wadman W.J., Hockberger P.E., Wong R.K. Sustained dendritic gradients of Ca2+ induced by excitatory amino acids in CA1 hippocampal neurons. Science. 240:1988;649-653.
58. 3H]ifenprodil binding in rat brain membranes. J Pharmacol Exp Ther. 280:1997;584-592.
59. Counihan T.J., Landwehrmeyer G.B., Standaert D.G., Kosinski C.M., Scherzer C.R., Daggett L.P., Velicelebi G., Young A.B., Penney J.B. Jr. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons. J Comp Neurol. 390:1998;91-101.
60. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 3:1996;241-253.
61. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
62. Crook J.M., Akil M., Law B.C., Hyde T.M., Kleinman J.E. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry. 7:2002;157-164.
63. Dall'Olio R., Gandolfi O. The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat. Psychopharmacology (Berl.). 110:1993;165-168.
64. Daly D.A., Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett. 152:1993;61-64.
65. Davies N., Russell A., Jones P., Murray R.M. Which characteristics of schizophrenia predate psychosis? J Psychiatr Res. 32:1998;121-131.
66. Davis G.W., Schuster C.M., Goodman C.S. Genetic dissection of structural and functional components of synaptic plasticity. III. CREB is necessary for presynaptic functional plasticity. Neuron. 17:1996;669-679.
67. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem. 52:1989;1781-1786.
68. De Blasi A., Conn P.J., Pin J., Nicoletti F. Molecular determinants of metabotropic glutamate receptor signaling. Trends Pharmacol Sci. 22:2001;114-120.
69. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 74:1997;129-140.
70. 2+/calmodulin-kinase II enhances channel conductance of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA. 96:1999;3269-3274.
71. De Souza I.E., McBean G.J., Meredith G.E. Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur J Pharmacol. 382:1999;139-142.
72. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience. 70:1996;377-389.
73. Devon R.S., Anderson S., Teague P.W., Muir W.J., Murray V., Pelosi A.J., Blackwood D.H., Porteous D.J. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry. 6:2001;311-314.
74. Doherty P., Fazeli M.S., Walsh F.S. The neural cell adhesion molecule and synaptic plasticity. J Neurobiol. 26:1995;437-446.
75. Done D.J., Crow T.J., Johnstone E.C., Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. Br Med J. 309:1994;699-703.
76. Dragunow M., Robertson G.S., Faull R.L., Robertson H.A., Jansen K. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294.
77. Driscoll M. Cell death in C. elegans: molecular insights into mechanisms conserved between nematodes and mammals. Brain Pathol. 6:1996;411-425.
78. Du Y., Bales K.R., Dodel R.C., Hamilton-Byrd E., Horn J.W., Czilli D.L., Simmons L.K., Ni B., Paul S.M. Activation of a caspase 3-related cysteine protease is required for glutamate-mediated apoptosis of cultured cerebellar granule neurons. Proc Natl Acad Sci USA. 94:1997;11657-11662.
79. Eastwood S.L., Burnet P.W., Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 66:1995;309-319.
80. Eastwood S.L., McDonald B., Burnet P.W., Beckwith J.P., Kerwin R.W., Harrison P.J. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res. 29:1995;211-223.
81. Eastwood S.L., Porter R.H., Harrison P.J. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain. Neurosci Lett. 212:1996;163-166.
82. Eastwood S.L., Burnet P.W., Harrison P.J. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res Mol Brain Res. 44:1997;92-98.
83. Eastwood S.L., Kerwin R.W., Harrison P.J. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry. 41:1997;636-643.
84. 2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci USA. 90:1993;755-759.
85. Emmett M.R., Mick S.J., Cler J.A., Rao T.S., Iyengar S., Wood P.L. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology. 30:1991;1167-1171.
86. Evins A.E., Amico E.T., Shih V., Goff D.C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm. 104:1997;761-766.
87. Evins A.E., Fitzgerald S.M., Wine L., Rosselli R., Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 157:2000;826-828.
88. 2+ stores and ion channels in neurons. Trends Neurosci. 23:2000;80-88.
89. Falke E., Han L.Y., Arnold S.E. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res. 93:2000;103-110.
90. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., St Peter H., Olney J.W. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia. Biol Psychiatry. 38:1995;788-796.
91. Farooqui A.A., Horrocks L.A. Lipid peroxides in the free radical pathophysiology of brain diseases. Cell Mol Neurobiol. 18:1998;599-608.
92. Fenton W.S. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 61(suppl. 4):2000;10-14.
93. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci. 15:1995;2453-2461.
94. Fix A.S., Wightman K.A., O'Callaghan J.P. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunocytochemistry. Neurotoxicology. 16:1995;229-237.
95. Flaum M., O'Leary D.S., Swayze V.W. 2nd, Miller D.D., Arndt S., Andreasen N.C. Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. J Psychiatr Res. 29:1995;261-276.
96. Fletcher E.J., MacDonald J.F. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur J Pharmacol. 235:1993;291-295.
97. Frank D.A., Greenberg M.E. CREB: a mediator of long-term memory from mollusks to mammals. Cell. 79:1994;5-8.
98. Frank E. Synapse elimination: for nerves it's all or nothing. Science. 275:1997;324-325.
99. Frerking M., Nicoll R.A. Synaptic kainate receptors. Curr Opin Neurobiol. 10:2000;342-351.
100. Friedman H.V., Bresler T., Garner C.C., Ziv N.E. Assembly of new individual excitatory synapses: time course and temporal order of synaptic molecular recruitment. Neuron. 27:2000;57-69.
101. Friston K.J., Frith C.D. Schizophrenia: a disconnection syndrome? Clin Neurosci. 3:1995;89-97.
102. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 24:2001;527-533.
103. Gallagher M.J., Huang H., Lynch D.R. Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. J Neurochem. 70:1998;2120-2128.
104. Gao X.-M., Sakai K., Roberts R.C., Conley R.R., Dean B., Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry. 157:2000;1141-1149.
105. Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., Barnes T.R., Hirsch S.R. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry. 65:1998;446-453.
106. Gauchy C., Desban M., Glowinski J., Kemel M.L. NMDA regulation of dopamine release from proximal and distal dendrites in the cat substantia nigra. Brain Res. 635:1994;249-256.
107. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 156:2001;117-154.
108. 2+/calmodulin-dependent protein kinase. J Neurosci. 20:2000;2766-2773.
109. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 57:2000;65-73.
110. Glazer W.M. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 61:2000;16-21.
111. Glazer W.M. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 61:2000;21-26.
112. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 158:2001;1367-1377.
113. Goff D.C., Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr Res. 27:1997;157-168.
114. Goff D.C., Tsai G., Beal M.F., Coyle J.T. Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry. 152:1995;1730-1736.
115. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
116. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 153:1996;1628-1630.
117. Goff D.C., Henderson D.C., Evins A.E., Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 45:1999;512-514.
118. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 56:1999;21-27.
119. Goff D.C., Leahy L., Berman I., Posever T., Herz L., Leon A.C., Johnson S.A., Lynch G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol. 21:2001;484-487.
120. Gomperts S.N., Rao A., Craig A.M., Malenka R.C., Nicoll R.A. Postsynaptically silent synapses in single neuron cultures. Neuron. 21:1998;1443-1451.
121. Grace A.A., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 20:1997;31-37.
122. Grauer S.M., Marquis K.L. Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology. 141:1999;405-412.
123. Grimwood S., Slater P., Deakin J.F., Hutson P.H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport. 10:1999;461-465.
124. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry. 155:1998;1711-1717.
125. Haas K. Prefabrication provides synapses on demand. Trends Neurosci. 23:2000;449.
126. Halliwell B., Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 57:1993;715S-725S.
127. Hamid E.H., Hyde T.M., Baca S.M., Egan M.F. Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia. Brain Res. 796:1998;291-295.
128. Harris K.M. Structure, development, and plasticity of dendritic spines. Curr Opin Neurobiol. 9:1999;343-348.
129. Harrison P.J. Schizophrenia: a disorder of neurodevelopment? Curr Opin Neurobiol. 7:1997;285-289.
130. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
131. 2 receptors are reversed by a blockade of N-methyl-D-aspartate receptors. Neuroscience. 73:1996;121-130.
132. Hauber W., Schmidt W.J. The NMDA antagonist dizocilpine (MK-801) reverses haloperidol-induced movement initiation deficits. Behav Brain Res. 41:1990;161-166.
133. Hayashi T., Kagaya A., Takebayashi M., Shimizu M., Uchitomi Y., Motohashi N., Yamawaki S. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther. 275:1995;207-214.
134. Heckers S. Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophr Bull. 23:1997;403-421.
135. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus. 11:2001;520-528.
136. Heckers S., Heinsen H., Heinsen Y., Beckmann H. Cortex, white matter, and basal ganglia in schizophrenia: a volumetric postmortem study. Biol Psychiatry. 29:1991;556-566.
137. Heckers S., Rauch S.L., Goff D., Savage C.R., Schacter D.L., Fischman A.J., Alpert N.M. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci. 1:1998;318-323.
138. Heckers S., Stone D., Walsh J., Shick J., Koul P., Benes F.M. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry. 59:2001;521-529.
139. Henderson G., Johnson J.W., Ascher P. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor. J Physiol (Lond.). 430:1990;189-212.
140. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
141. Heresco-Levy U., Silipo G., Javitt D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull. 32:1996;731-740.
142. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 56:1999;29-36.
143. Herron C.E., Lester R.A., Coan E.J., Collingridge G.L. Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism. Nature. 322:1986;265-268.
144. Hirashima Y., Kurimoto M., Nogami K., Endo S., Saitoh M., Ohtani O., Nagata T., Muraguchi A., Takaku A. Correlation of glutamate-induced apoptosis with caspase activities in cultured rat cerebral cortical neurons. Brain Res. 849:1999;109-118.
145. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 17:1994;31-108.
146. Hood W.F., Compton R.P., Monahan J.B. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett. 98:1989;91-95.
147. Hume R.I., Dingledine R., Heinemann S.F. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science. 253:1991;1028-1031.
148. Huttenlocher P.R. Synapse elimination and plasticity in developing human cerebral cortex. Am J Ment Defic. 88:1984;488-496.
149. Huttenlocher P.R., de Courten C., Garey L.J., Van der Loos H. Synaptogenesis in human visual cortex - evidence for synapse elimination during normal development. Neurosci Lett. 33:1982;247-252.
150. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 153:1996;151-162.
151. Illowsky B.P., Juliano D.M., Bigelow L.B., Weinberger D.R. Stability of CT scan findings in schizophrenia: results of an 8 year follow-up study. J Neurol Neurosurg Psychiatry. 51:1988;209-213.
152. Ilyin V.I., Whittemore E.R., Guastella J., Weber E., Woodward R.M. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol Pharmacol. 50:1996;1541-1550.
153. Impey S., Smith D.M., Obrietan K., Donahue R., Wade C., Storm D.R. Stimulation of cAMP response element (CRE)-mediated transcription during contextual learning. Nat Neurosci. 1:1998;595-601.
154. Isaac J.T., Nicoll R.A., Malenka R.C. Evidence for silent synapses: implications for the expression of LTP. Neuron. 15:1995;427-434.
155. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry. 35:1994;84-95.
156. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
157. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
158. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
159. Jernigan T.L., Zisook S., Heaton R.K., Moranville J.T., Hesselink J.R., Braff D.L. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Arch Gen Psychiatry. 48:1991;881-890.
160. Jia Z., Lu Y., Henderson J., Taverna F., Romano C., Abramow-Newerly W., Wojtowicz J.M., Roder J. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn Mem. 5:1998;331-343.
161. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
162. Johnson S.A., Luu N.T., Herbst T.A., Knapp R., Lutz D., Arai A., Rogers G.A., Lynch G. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther. 289:1999;392-397.
163. Jones D.G., Harris R.J. An analysis of contemporary morphological concepts of synaptic remodelling in the CNS: perforated synapses revisited. Rev Neurosci. 6:1995;177-219.
164. Jones P., Rodgers B., Murray R., Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 344:1994;1398-1402.
165. Jones P.B., Rantakallio P., Hartikainen A.L., Isohanni M., Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am J Psychiatry. 155:1998;355-364.
166. Joo A., Shibata H., Ninomiya H., Kawasaki H., Tashiro N., Fukumaki Y. Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia. Mol Psychiatry. 6:2001;186-192.
167. Kandel E.R., Schwartz J.H., Jessell T.M. Principles of Neural Science. 3rd edn. 1991;Elsevier, New York.
168. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 155:1998;921-928.
169. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 156:1999;286-293.
170. Kaur S., Ozer H., Starr M. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur J Pharmacol. 332:1997;153-160.
171. Kelsoe J.R., Cadet J.L., Pickar D., Weinberger D.R. Quantitative neuroanatomy in schizophrenia. A controlled magnetic resonance imaging study. Arch Gen Psychiatry. 45:1988;533-541.
172. Kerns J.M., Sierens D.K., Kao L.C., Klawans H.L., Carvey P.M. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol. 15:1992;488-500.
173. Kerwin R., Patel S., Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience. 39:1990;25-32.
174. Keshavan M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., Pettegrew J.W. Changes in caudate volume with neuroleptic treatment. Lancet. 344:1994;1434.
175. Keyser D.O., Alger B.E. Arachidonic acid modulates hippocampal calcium current via protein kinase C and oxygen radicals. Neuron. 5:1990;545-553.
176. Khodorov B.I. Mechanisms of destabilization of Ca2+-homeostasis of brain neurons caused by toxic glutamate challenge. Membr Cell Biol. 14:2000;149-162.
177. Kilts C.D. The changing roles and targets for animal models of schizophrenia. Biol Psychiatry. 50:2001;845-855.
178. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 20:1980;379-382.
179. Kirov S.A., Sorra K.E., Harris K.M. Slices have more synapses than perfusion-fixed hippocampus from both young and mature rats. J Neurosci. 19:1999;2876-2886.
180. 2-like receptors inhibit excitatory transmission onto rat ventral tegmental dopaminergic neurones. J Physiol. 523:2000;163-173.
181. Kohler M., Burnashev N., Sakmann B., Seeburg P.H. Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing. Neuron. 10:1993;491-500.
182. Konradi C., Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry. 50:2001;729-742.
183. Kornhuber J., Mack-Burkhardt F., Riederer P., Hebenstreit G.F., Reynolds G.P., Andrews H.B., Beckmann H. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm. 77:1989;231-236.
184. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51:1994;199-214.
185. Kunugi H., Takei N., Murray R.M., Saito K., Nanko S. Small head circumference at birth in schizophrenia. Schizophr Res. 20:1996;165-170.
186. Kure S., Tominaga T., Yoshimoto T., Tada K., Narisawa K. Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem Biophys Res Commun. 179:1991;39-45.
187. Laube B., Hirai H., Sturgess M., Betz H., Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron. 18:1997;493-503.
188. Lavalaye J., Linszen D.H., Booij J., Reneman L., Gersons B.P., van Royen E.A. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res. 92:1999;33-44.
189. Lazarewicz J.W., Wroblewski J.T., Costa E. N-methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells. J Neurochem. 55:1990;1875-1881.
190. Lee S.H., Sheng M. Development of neuron-neuron synapses. Curr Opin Neurobiol. 10:2000;125-131.
191. Lerma J., Paternain A.V., Rodriguez-Moreno A., Lopez-Garcia J.C. Molecular physiology of kainate receptors. Physiol Rev. 81:2001;971-998.
192. Leveque J.-C., Macías W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., Li X.-M., Coyle J.T., Huganir R.L., Heckers S., Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci. 20:2000;4011-4020.
193. Levinson D.F. Pharmacologic treatment of schizophrenia. Clin Ther. 13:1991;326-352.
194. Lewis D.A., Lieberman J.A. Catching up on schizophrenia. Natural history and neurobiology. Neuron. 28:2000;325-334.
195. Liao D., Hessler N.A., Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature. 375:1995;400-404.
196. 4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther. 283:1997;939-946.
197. Lidsky T.I., Yablonsky-Alter E., Zuck L.G., Banerjee S.P. Antipsychotic drug effects on glutamatergic activity. Brain Res. 764:1997;46-52.
198. 2+-dependent phosphatase. Nature. 369:1994;235-239.
199. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 46:1999;729-739.
200. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 50:2001;884-897.
201. Lim K.O., Tew W., Kushner M., Chow K., Matsumoto B., DeLisi L.E. Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J Psychiatry. 153:1996;1548-1553.
202. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 23:2000;223-239.
203. Littrell K.H., Johnson C.G., Littrell S., Peabody C.D. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry. 55:1998;279-280.
204. Liu X., Zou H., Slaughter C., Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 89:1997;175-184.
205. Luetjens C.M., Bui N.T., Sengpiel B., Munstermann G., Poppe M., Krohn A.J., Bauerbach E., Krieglstein J., Prehn J.H. Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. J Neurosci. 20:2000;5715-5723.
206. Lynch D.R., Gallagher M.J. Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther. 279:1996;154-161.
207. MacDermott A.B., Mayer M.L., Westbrook G.L., Smith S.J., Barker J.L. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature. 321:1986;519-522.
208. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain Res. 23:1994;21-32.
209. Malenka R.C. The role of postsynaptic calcium in the induction of long-term potentiation. Mol Neurobiol. 5:1991;289-295.
210. Malenka R.C., Nicoll R.A. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. 16:1993;521-527.
211. Malenka R.C., Nicoll R.A. Long-term potentiation - a decade of progress? Science. 285:1999;1870-1874.
212. Mammen A.L., Kameyama K., Roche K.W., Huganir R.L. Phosphorylation of the α-amino-3-hydroxy-5-methylisoxazole4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II. J Biol Chem. 272:1997;32528-32533.
213. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biology on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
214. Marsh L., Suddath R.L., Higgins N., Weinberger D.R. Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness. Schizophr Res. 11:1994;225-238.
215. Martin K.C., Casadio A., Zhu H.E.Y., Rose J.C., Chen M., Bailey C.H., Kandel E.R. Synapse-specific, long-term facilitation of aplysia sensory to motor synapses: a function for local protein synthesis in memory storage. Cell. 91:1997;927-938.
216. Martin L.J., Al-Abdulla N.A., Brambrink A.M., Kirsch J.R., Sieber F.E., Portera-Cailliau C. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res Bull. 46:1998;281-309.
217. Martinou J.C., Sadoul R. ICE-like proteases execute the neuronal death program. Curr Opin Neurobiol. 6:1996;609-614.
218. Matthysse S. Dopamine and the pharmacology of schizophrenia: the state of the evidence. J Psychiatr Res. 11:1974;107-113.
219. Mattson M.P. Neurotransmitters in the regulation of neuronal cytoarchitecture. Brain Res. 472:1988;179-212.
220. Mayer M.L., Westbrook G.L., Guthrie P.B. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 309:1984;261-263.
221. McNeil T.F., Cantor-Graae E., Torrey E.F., Sjostrom K., Bowler A., Taylor E., Rawlings R., Higgins E.S. Obstetric complications in histories of monozygotic twins discordant and concordant for schizophrenia. Acta Psychiatr Scand. 89:1994;196-204.
222. Meador-Woodruff J.H., Healy D.J. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev. 31:2000;288-294.
223. Meltzer H.Y. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 55(suppl. B):1994;47-52.
224. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106S-115S.
225. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 2:1976;19-76.
226. Meltzer L.T., Christoffersen C.L., Serpa K.A. Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev. 21:1997;511-518.
227. Mermelstein P.G., Bito H., Deisseroth K., Tsien R.W. Critical dependence of cAMP response element-binding protein phosphorylation on L-type calcium channels supports a selective response to EPSPs in preference to action potentials. J Neurosci. 20:2000;266-273.
228. Merry D.E., Korsmeyer S.J. Bcl-2 gene family in the nervous system. Annu Rev Neurosci. 20:1997;245-267.
229. Meshul C.K., Casey D.E. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res. 489:1989;338-346.
230. Meshul C.K., Bunker G.L., Mason J.N., Allen C., Janowsky A. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J Neurochem. 67:1996;1965-1973.
231. Metzstein M.M., Stanfield G.M., Horvitz H.R. Genetics of programmed cell death in C. elegans: past, present and future. Trends Genet. 14:1998;410-416.
232. Micheletti G., Lannes B., Warter J.M., Zwiller J. Evidence for NMDA/D2 receptor-receptor interactions in the rat striatum. Adv Neurol. 60:1993;128-132.
233. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci. 21:2001;750-757.
234. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
235. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 98:1999;427-436.
236. Montal M. Mitochondria, glutamate neurotoxicity and the death cascade. Biochim Biophys Acta. 1366:1998;113-126.
237. Moore N.A., Blackman A., Awere S., Leander J.D. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Eur J Pharmacol. 237:1993;1-7.
238. Morari M., Marti M., Sbrenna S., Fuxe K., Bianchi C., Beani L. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem Int. 33:1998;383-397.
239. Murase S., Schuman E.M. The role of cell adhesion molecules in synaptic plasticity and memory. Curr Opin Cell Biol. 11:1999;549-553.
240. Murphy S.N., Miller R.J. A glutamate receptor regulates Ca2+ mobilization in hippocampal neurons. Proc Natl Acad Sci USA. 85:1988;8737-8741.
241. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603.
242. Nasrallah H.A., Olson S.C., McCalley-Whitters M., Chapman S., Jacoby C.G. Cerebral ventricular enlargement in schizophrenia. A preliminary follow-up study. Arch Gen Psychiatry. 43:1986;157-159.
243. Nath R., Probert A. Jr., McGinnis K.M., Wang K.K. Evidence for activation of caspase-3-like protease in excitotoxin- and hypoxia/hypoglycemia-injured neurons. J Neurochem. 71:1998;186-195.
244. Nath R., Scott M., Nadimpalli R., Gupta R., Wang K.K. Activation of apoptosis-linked caspase(s) in NMDA-injured brains in neonatal rats. Neurochem Int. 36:2000;119-126.
245. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA. 89:1992;4270-4274.
246. Nicoll R.A., Malenka R.C. Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann NY Acad Sci. 868:1999;515-525.
247. Nishi M., Hinds H., Lu H.P., Kawata M., Hayashi Y. Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J Neurosci. 21:2001;RC185.
248. Nishikawa T., Takashima M., Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett. 40:1983;245-250.
249. Noga J.T., Hyde T.M., Herman M.M., Spurney C.F., Bigelow L.B., Weinberger D.R., Kleinman J.E. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse. 27:1997;168-176.
250. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 152:1995;1444-1449.
251. Nudmamud S., Reynolds G.P. Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophrenia. Neurosci Lett. 304:2001;9-12.
252. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
253. O'Callaghan E., Larkin C., Kinsella A., Waddington J.L. Familial, obstetric, and other clinical correlates of minor physical anomalies in schizophrenia. Am J Psychiatry. 148:1991;479-483.
254. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res. 56:1998;207-217.
255. Ohnuma T., Tessler S., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res. 85:2000;24-31.
256. Ohtsuki T., Toru M., Arinami T. Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia. Psychiatr Genet. 11:2001;79-83.
257. Olney J.W. Excitatory transmitter neurotoxicity. Neurobiol Aging. 15:1994;259-260.
258. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
259. Olney J.W., Price M.T., Samson L., Labruyere J. The role of specific ions in glutamate neurotoxicity. Neurosci Lett. 65:1986;65-71.
260. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
261. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518.
262. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 33:1999;523-533.
263. Omkumar R.V., Kiely M.J., Rosenstein A.J., Min K.T., Kennedy M.B. Identification of a phosphorylation site for calcium/calmodulin-dependent protein kinase II in the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 271:1996;31670-31678.
264. Ozawa S., Kamiya H., Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol. 54:1998;581-618.
265. 2+-permeable AMPA receptors in neurological disorders. Trends Neurosci. 20:1997;464-470.
266. Pellicciari R., Costantino G. Metabotropic G-protein-coupled glutamate receptors as therapeutic targets. Curr Opin Chem Biol. 3:1999;433-440.
267. Perez-Otano I., Schulteis C.T., Contractor A., Lipton S.A., Trimmer J.S., Sucher N.J., Heinemann S.F. Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors. J Neurosci. 21:2001;1228-1237.
268. Petersen R.C., Stillman R.C. Phencyclidine: an overview. NIDA Res Monogr. 21:1978;1-17.
269. Petralia R.S., Esteban J.A., Wang Y.X., Partridge J.G., Zhao H.M., Wenthold R.J., Malinow R. Selective acquisition of AMPA receptors over postnatal development suggests a molecular basis for silent synapses. Nat Neurosci. 2:1999;31-36.
270. Pfefferbaum A., Zipursky R.B., Lim K.O., Zatz L.M., Stahl S.M., Jernigan T.L. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Arch Gen Psychiatry. 45:1988;633-640.
271. Pilowsky L.S., Busatto G.F., Taylor M., Costa D.C., Sharma T., Sigmundsson T., Ell P.J., Nohria V., Kerwin R.W. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology. 124:1996;148-153.
272. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G., Calabresi P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience. 106:2001;579-587.
273. Platenik J., Kuramoto N., Yoneda Y. Molecular mechanisms associated with long-term consolidation of the NMDA signals. Life Sci. 67:2000;335-364.
274. Porter R.H., Eastwood S.L., Harrison P.J. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751:1997;217-231.
275. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry. 156:1999;145-147.
276. Prinssen E.P., Ellenbroek B.A., Cools A.R. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol. 262:1994;167-170.
277. Puri B.K., Barnes T.R.E., Chapman M.J., Hutton S.B., Joyce E.M. Spontaneous dyskinesia in first episode schizophrenia. J Neurol Neurosurg Psychiatry. 66:1998;76-78.
278. Racca C., Stephenson F.A., Streit P., Roberts J.D., Somogyi P. NMDA receptor content of synapses in stratum radiatum of the hippocampal CA1 area. J Neurosci. 20:2000;2512-2522.
279. Raedler T.J., Knable M.B., Lafargue T., Urbina R.A., Egan M.F., Pickar D., Weinberger D.R. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res. 90:1999;81-90.
280. 2+ channels are essential for glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal neurons. J Neurosci. 19:1999;6348-6359.
281. Randall R.D., Thayer S.A. Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons. J Neurosci. 12:1992;1882-1895.
282. Rao P.S., Ayres S.M., Mueller H.S. Identity of peroxy radicals produced from arachidonic acid in oxygenated solutions as studied by pulse radiolysis technique. Biochem Biophys Res Commun. 104:1982;1532-1536.
283. Remington G., Chong S.A. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci. 24:1999;431-441.
284. Remington G., Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry. 60:1999;15-19.
285. Richardson-Burns S.M., Haroutunian V., Davis K.L., Watson S.J., Meador-Woodruff J.H. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry. 47:2000;22-28.
286. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 60:1999;5-14.
287. Roberts G.W., Colter N., Lofthouse R., Bogerts B., Zech M., Crow T.J. Gliosis in schizophrenia: a survey. Biol Psychiatry. 21:1986;1043-1050.
288. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
289. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 271:1994;1058-1066.
290. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 56:1999;241-247.
291. Rongo C., Kaplan J.M. CaMKII regulates the density of central glutamatergic synapses in vivo. Nature. 402:1999;195-199.
292. Rosenmund C., Stern-Bach Y., Stevens C.F. The tetrameric structure of a glutamate receptor channel. Science. 280:1998;1596-1599.
293. Rosso I.M., Bearden C.E., Hollister J.M., Gasperoni T.L., Sanchez L.E., Hadley T., Cannon T.D. Childhood neuromotor dysfunction in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull. 26:2000;367-378.
294. Rothman S.M. The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J Neurosci. 5:1985;1483-1489.
295. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci. 18:1995;57-58.
296. Safferling M., Tichelaar W., Kummerle G., Jouppila A., Kuusinen A., Keinanen K., Madden D.R. First images of a glutamate receptor ion channel: oligomeric state and molecular dimensions of GluRB homomers. Biochemistry. 40:2001;13948-13953.
297. Sattler R., Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity. J Mol Med. 78:2000;3-13.
298. Schinder A.F., Olson E.C., Spitzer N.C., Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci. 16:1996;6125-6133.
299. Schoepp D.D. The biochemical pharmacology of metabotropic glutamate receptors. Biochem Soc Trans. 21:1993;97-102.
300. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther. 299:2001;12-20.
301. Schulman H. Protein phosphorylation in neuronal plasticity and gene expression. Curr Opin Neurobiol. 5:1995;375-381.
302. Schwartz L.M., Milligan C.E. Cold thoughts of death: the role of ICE proteases in neuronal cell death. Trends Neurosci. 19:1996;555-562.
303. Sebens J.B., Koch T., Ter Horst G.J., Korf J. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur J Pharmacol. 273:1995;175-182.
304. See R.E., Chapman M.A., Meshul C.K. Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse. 12:1992;147-154.
305. Seeburg P.H. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 16:1993;359-365.
306. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7:1992;261-284.
307. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 188:1975;1217-1219.
308. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 6:1993;602-608.
309. 4 receptors. Neuropsychopharmacology. 16:1997;93-110.
310. Segal M. Rapid plasticity of dendritic spine: hints to possible functions? Prog Neurobiol. 63:2001;61-70.
311. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry. 45:1999;17-25.
312. Sengpiel B., Preis E., Krieglstein J., Prehn J.H. NMDA-induced superoxide production and neurotoxicity in cultured rat hippocampal neurons: role of mitochondria. Eur J Neurosci. 10:1998;1903-1910.
313. 2+-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science. 252:1991;1427-1430.
314. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett. 121:1991;77-80.
315. Shi J., Townsend M., Constantine-Paton M. Activity-dependent induction of tonic calcineurin activity mediates a rapid developmental downregulation of NMDA receptor currents. Neuron. 28:2000;103-114.
316. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Harvey P.D., Newman A., Schnur D.B., Spiegel-Cohen J., Wei T., Machac J., Knesaurek K., Vallabhajosula S., Biren M.A., Ciaravolo T.M., Luu-Hsia C. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry. 55:1998;235-243.
317. Simonian N.A., Getz R.L., Leveque J.C., Konradi C., Coyle J.T. Kainic acid induces apoptosis in neurons. Neuroscience. 75:1996;1047-1055.
318. Simpson M.D., Slater P., Royston M.C., Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res. 6:1991;41-48.
319. Smith Y., Charara A., Parent A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol. 364:1996;231-253.
320. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry. 130:1973;61-67.
321. Snyder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 133:1976;197-202.
322. Soderling T.R. Calcium/calmodulin-dependent protein kinase II: role in learning and memory. Mol Cell Biochem. 127-128:1993;93-101.
323. Sommer B., Kohler M., Sprengel R., Seeburg P.H. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell. 67:1991;11-19.
324. Stockmeier C.A., DiCarlo J.J., Zhang Y., Thompson P., Meltzer H.Y. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther. 266:1993;1374-1384.
325. Sucher N.J., Akbarian S., Chi C.L., Leclerc C.L., Awobuluyi M., Deitcher D.L., Wu M.K., Yuan J.P., Jones E.G., Lipton S.A. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci. 15:1995;6509-6520.
326. Sun L., Margolis F.L., Shipley M.T., Lidow M.S. Identification of a long variant of mRNA encoding the NR3 subunit of the NMDA receptor: its regional distribution and developmental expression in the rat brain. FEBS Lett. 441:1998;392-396.
327. 2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev. 8:1994;2527-2539.
328. Supplisson S., Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci. 17:1997;4580-4590.
329. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull. 24:1998;285-301.
330. Swerdlow N.R., Bakshi V., Waikar M., Taaid N., Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacologia. 140:1998;75-80.
331. Swope S.L., Moss S.I., Raymond L.A., Huganir R.L. Regulation of ligand-gated ion channels by protein phosphorylation. Adv Second Messenger Phosphoprot Res. 33:1999;49-78.
332. Tan S.E., Wenthold R.J., Soderling T.R. Phosphorylation of AMPA-type glutamate receptors by calcium/calmodulin-dependent protein kinase II and protein kinase C in cultured hippocampal neurons. J Neurosci. 14:1994;1123-1129.
333. Tandon R., Milner K., Jibson M.D. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry. 60:1999;21-28.
334. Tenneti L., Lipton S.A. Involvement of activated caspase-3-like proteases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem. 74:2000;134-142.
335. Tenneti L., D'Emilia D.M., Troy C.M., Lipton S.A. Role of caspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem. 71:1998;946-959.
336. Thompson S.M. Synaptic plasticity: building memories to last. Curr Biol. 10:2000;R218-R221.
337. Tong G., Shepherd D., Jahr C.E. Synaptic desensitization of NMDA receptors by calcineurin. Science. 267:1995;1510-1512.
338. Toni N., Buchs P.-A., Nikonenko I., Bron C.R., Muller D. LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. Nature. 402:1999;421-425.
339. Travis M.J., Busatto G.F., Pilowsky L.S., Mulligan R., Acton P.D., Gacinovic S., Mertens J., Terriere D., Costa D.C., Ell P.J., Kerwin R.W. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br J Psychiatry. 173:1998;236-241.
340. 2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry. 155:1998;505-508.
341. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 155:1998;1207-1213.
342. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 44:1998;1081-1089.
343. Tsai G.E., Yang P., Chung L.C., Tsai I.C., Tsai C.W., Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 156:1999;1822-1825.
344. Uranova N.A., Orlovskaya D.D., Apel K., Klintsova A.J., Haselhorst U., Schenk H. Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse. 7:1991;253-259.
345. Vita A., Dieci M., Giobbio G.M., Tenconi F., Invernizzi G. Time course of cerebral ventricular enlargement in schizophrenia supports the hypothesis of its neurodevelopmental nature. Schizophr Res. 23:1997;25-30.
346. Wahlbeck K., Forsen T., Osmond C., Barker D.J., Eriksson J.G. Association of schizophrenia with low maternal body mass index, small size at birth, and thinness during childhood. Arch Gen Psychiatry. 58:2001;48-52.
347. Walker E.F., Grimes K.E., Davis D.M., Smith A.J. Childhood precursors of schizophrenia: facial expressions of emotion. Am J Psychiatry. 150:1993;1654-1660.
348. Walker E.F., Savoie T., Davis D. Neuromotor precursors of schizophrenia. Schizophr Bull. 20:1994;441-451.
349. Wan W., Ennulat D.J., Cohen B.M. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res. 688:1995;95-104.
350. Wang Y.T., Salter M.W. Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature. 369:1994;233-235.
351. Watson C.G., Kucala T., Tilleskjor C., Jacobs L. Schizophrenic birth seasonality in relation to the incidence of infectious diseases and temperature extremes. Arch Gen Psychiatry. 41:1984;85-90.
352. Watson G.B., Bolanowski M.A., Baganoff M.P., Deppeler C.L., Lanthorn T.H. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 510:1990;158-160.
353. Weinberger D.R., Torrey E.F., Neophytides A.N., Wyatt R.J. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry. 36:1979;735-739.
354. Weissman A.D., Casanova M.F., Kleinman J.E., London E.D., De Souza E.B. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry. 29:1991;41-54.
355. Willinger U., Heiden A.M., Meszaros K., Formann A.K., Aschauer H.N. Neurodevelopmental schizophrenia: obstetric complications, birth weight, premorbid social withdrawal and learning disabilities. Neuropsychobiology. 43:2001;163-169.
356. Wong W.T., Wong R.O. Rapid dendritic movements during synapse formation and rearrangement. Curr Opin Neurobiol. 10:2000;118-124.
357. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry. 155:1998;1661-1670.
358. Wright P., Takei N., Rifkin L., Murray R.M. Maternal influenza, obstetric complications, and schizophrenia. Am J Psychiatry. 152:1995;1714-1720.
359. Wu G., Malinow R., Cline H.T. Maturation of a central glutamatergic synapse. Science. 274:1996;972-976.
360. 2+/calmodulin-dependent protein kinase II regulatory phosphorylation site in non-N-methyl-D-aspartate glutamate receptors. Proc Natl Acad Sci USA. 92:1995;1376-1380.
361. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci. 14:1994;4159-4166.
362. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem. 58:1992;1736-1742.
363. Yin J.C., Wallach J.S., Del Vecchio M., Wilder E.L., Zhou H., Quinn W.G., Tully T. Induction of a dominant negative CREB transgene specifically blocks long-term memory in Drosophila. Cell. 79:1994;49-58.
364. Yin J.C., Del Vecchio M., Zhou H., Tully T. CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell. 81:1995;107-115.
365. Yoshida Y., Ono T., Kizu A., Fukushima R., Miyagishi T. Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur J Pharmacol. 203:1991;173-180.
366. Ziolkowska B., Hollt V. The NMDA receptor antagonist MK-801 markedly reduces the induction of c-fos gene by haloperidol in the mouse striatum. Neurosci Lett. 156:1993;39-42.
367. Zipursky R.B., Lim K.O., Sullivan E.V., Brown B.W., Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry. 49:1992;195-205.
368. Zorn S.H., Jones S.B., Ward K.M., Liston D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 269:1994;R1-R2.
369. Zou H., Henzel W.J., Liu X., Lutschg A., Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 90:1997;405-413.